Long-wavelength UVA (340-400 nm UVA-1) phototherapy has been reported to be effective in atopic dermatitis, localized scleroderma and T-cell-derived skin diseases. We retrospectively investigated 70 patients with acute cutaneous GVHD after allogeneic haematopoietic cell transplantation or donor lymphocyte infusion. Complete and partial responses with a median duration of 10 months were achieved in 49 (70%) and 17 (24.3%) patients, respectively. Overall, 47 (67.1%) patients were not treated with systemic steroids. Furthermore, immunosuppression could be tapered in 24 (34.3%) patients while they were receiving UVA-1 treatment. Responses were seen irrespective of age or type of conditioning. Treatment was very well tolerated. After a median follow-up of 18 (range 10-60) months, three patients developed epithelial skin neoplasia. We conclude that UVA-1 therapy is feasible, well tolerated and can be an effective treatment for acute GVHD of the skin, thereby avoiding the use of systemic steroids and/or allowing a more rapid tapering of systemic immunosuppression in a substantial number of patients. The results of this retrospective analysis warrant larger, prospective studies and the effectiveness of UVA-1 therapy should be compared with other established treatment modalities.
Introduction
Barriers to successful haematopoietic cell transplantation (HCT) include risk of disease relapse, graft failure and the possible induction of severe acute and chronic GVHD. 1, 2 Acute GVHD is a complex problem and to date its pathophysiology is not understood in depth. As published by Ferrara and Yanik, 2 it can be considered as a three-step process, comprising tissue damaging to the recipient by pretransplant radiation or chemotherapy, donor T-cell activation and clonal expansion, and cellular and inflammatory factors. Acute GVHD has been shown to reduce the risk of haematological disease relapse, as it may be associated with a graft-vs-tumour effect. 3 However, severe acute GVHD is a serious complication after HCT, resulting in considerable morbidity and mortality. GVHD occurs in 30-60% of patients after HCT from an HLA-identical related donor and in 50-80% of patients receiving a transplant from HLA-matched unrelated donors. [4] [5] [6] [7] Involvement of the skin is the most frequent manifestation of GVHD besides its effect on liver or gut. 1 Various immunosuppressive medications, including CsA, MTX, mycophenolate mofetil (MMF) and others, are used to prevent acute GVHD. Despite a steady increase in the repertoire of available drugs, glucocorticoids remain the first-line therapy for patients who develop acute GVHD, often in combination with other agents such as antithymocyte globulin, CsA, tacrolimus (FK506), MMF or monoclonal antibodies. 1, 2, [8] [9] [10] [11] A major side effect of systemic glucocorticoids is an increased risk of infection and of relapse of the underlying malignancy. 8, 12 In addition, only 20-40% of patients show a durable response to first-line glucocorticoid treatment. 11 These results emphasize the need for new treatment options for acute GVHD.
Extracorporeal photopheresis in glucocorticoid-refractory acute and chronic GVHD has been shown to be effective in pilot studies. 13 Larger clinical trials treating patients with acute GVHD with ECP are currently under way. Also, promising results have been shown for patients treated for acute cutaneous GVHD with photochemotherapy with 8-methyoxypsoralen plus UV light. [14] [15] [16] Long-wavelength UVA (340-400 nm UVA-1) phototherapy has been described as a successful treatment option for atopic dermatitis, localized scleroderma and other T-cellderived skin diseases. [17] [18] [19] [20] [21] [22] [23] [24] Equipment capable of delivering this waveband has been available since 1981, but only over the past decade have studies assessing the therapeutic potential of UVA-1 been published. UVA-1 irradiation has many advantages over classic 8-methyoxypsoralen plus UV light therapy. In UVA-1 therapy, no UV-sensitizing regimen is necessary. Patients do not have to take a bath or systemic application of psoralen, risk of sun protection is lowered and treatment time is minimized. Currently, UVA-1 is regarded as being less carcinogenic than 8-methyoxypsoralen plus UV light.. 17 UVA-1 irradiation is effective in the treatment of inflammatory skin diseases. 18, 19 With regard to GVHD, publications indicate that UVA-1 induces apoptosis of skin-infiltrating T-cells. Ambach et al. showed a dose-and wavelength-dependent UVA-1 effect in vitro on the major effector system of perforin-granules in CTL in the skin. Other effects such as downregulated IFN-g expression in skin lesions of atopic dermatitis and a reduction of inflammatory infiltrates in the skin by UVA-1 irradiation have also been shown. [20] [21] [22] [23] UVA-1 also caused phenotypic and functional maturation of migrating dermal DCs into potent APCs. These data underline the evidence for UVA's immunosuppressive abilities. 24 In a pilot study, Wetzig et al. 25 reported on seven patients who received UVA-1 as primary therapy for acute cutaneous GVHD. Five patients achieved a complete response with no relapse at a median follow-up of 9 months after UVA-1. Two patients showed no response and systemic glucocorticoids were required.
On the basis of these promising results, we treated 70 patients with acute cutaneous GVHD with UVA-1 at the University of Leipzig with exceptionally good results. Factors that may influence the efficacy of UVA-1, such as age and type of conditioning regimen (reduced intensity conditioning (RIC) vs more intensive conditioning), were retrospectively analysed. In addition, the incidence of chronic GVHD of the skin and the incidence of secondary skin neoplasia were studied.
Patients and methods
From 2003 to 2007, a total of 70 patients (34 females and 36 males) at a median age of 53 (range 25-74) years with acute cutaneous GVHD after HCT or donor lymphocyte infusion (DLI) were treated with UVA-1 irradiation at the University of Leipzig after obtaining informed consent. AML was the most frequent reason for performing HCT (27 (38.6%) patients). Peripheral blood was the stem cell source in all but one patient who received BM. Donors were matched related donor in 22 (31.4%) patients and matched unrelated donors in 48 (68.6%) patients. RIC (fludarabine 30 mg/m 2 /day for 3 days followed by TBI 2 Gy), immunosuppression with cyclosporine (through level X200 ng/mL) and MMF was given to 43 (61.4%) patients.
Conventional conditioning with 12 Gy TBI and CY 60 mg/kg body weight/day for 2 days was given to 19 (27.2%) patients. Rabbit antithymocyte globulin 15 mg/kg body weight/day for 3 consecutive days was given to 10/19 patients, who received a transplant from a matched unrelated donor after conventional conditioning. GVHD prophylaxis after conventional conditioning consisted of CsA (through level X200 ng/mL) and MTX.
Eight (11.4%) patients had various conditioning regimens owing to disease and donor-specific characteristics: two patients received haploidentical transplantation after conditioning with 12 Gy TBI, thiotepa 2 Â 5 mg/kg, fludar- Patients were seen regularly at least once a week by a haematologist at our institution in the first months after transplantation. All patients suffered from acute cutaneous GVHD at a median of 31 (range 15-90) days after HCT or DLI.
The diagnosis of acute GVHD was made clinically as well as histologically. Staging and grading of GVHD were performed according to the Glucksberg-Seattle criteria. 26 Patients with stage 2 skin GVHD were eligible for UVA-1 therapy, only if there was progression of disease or no improvement within 7 days despite topical steroids. For stage 3 skin disease at diagnosis, UVA-1 therapy was started immediately. At the time of onset of GVHD, prophylactic immunosuppression was continued in all patients.
Progressive stage 2 skin GVHD was present in 47 (67.1%), stage 3 in 21 (30%) and stage 4 GVHD in 2 (2.9%) patients. In addition to skin involvement, 19 (27.1%) patients suffered from gastrointestinal and/or hepatic GVHD. Only a few patients (n ¼ 7) with simultaneous skin and extracutaneous stage 1 acute GVHD were treated with phototherapy alone without systemic steroids. The remaining 12/19 patients were treated simultaneously with UVA-1 and systemic steroids.
Overall, 33 (47.15%), 26 (37.15%) and 11 (15.7%) patients suffered from grade I, grade II and grade III GVHD, respectively. Severity of acute GVHD after RIC was grade I in 18 (42%), grade II in 18 (42%) and grade III in 7 (16%) patients. For patients after non-RIC-HCT, acute GVHD was grade I in 15 (55%), grade II in 8 (30%) and grade III in 4 (15%).
In total, 47 (67.1%) patients, including 7 patients with cutaneous GVHD stage 3 did not receive steroids, but were offered UVA-1 treatment as primary treatment. For the remaining 23 (32.9%) patients, including all patients with grade III disease, methylprednisolone 2-10 mg/kg body weight/day was started simultaneously with UVA-1 therapy as primary treatment. Patient characteristics are shown in Table 1 .
Indications for systemic steroids with UVA-1 therapy were rapidly evolving from stage 2 to stage 3 skin GVHD within 7 days despite topical steroids and all grade III acute GVHD. For assessment of response, all patients were seen twice weekly by a haematologist and once weekly by a dermatologist at the University of Leipzig. Usually, and in the absence of UVA-1 therapy, the schedule of tapering steroids for patients with documented response at our institution is as follows: the evening dose of methylprednisolone is tapered by 0.2 mg/kg every 5 days followed by a successive taper of the morning dose by 0.2 mg/kg at 5 days intervals. At a daily dose level of 15 mg, the usual alternate UVA-1 in acute GVHD of the skin M Schlaak et al day taper schedule is given over 2 weeks to allow recovery of adrenal function. With CR after UVA-1 therapy, steroids were tapered more rapidly (every 2-3) days. For patients not receiving steroids and achieving a CR with UVA-1 therapy, MMF (in patients with RIC-HCT) was reduced by 500 mg every 2 weeks followed by 25 mg cyclosporine reduction per day every 7-10 days. For patients not receiving MMF, 25 mg cyclosporine, reduction per day every 7-10 days was undertaken. For patients with a PR on UVA-1 therapy and systemic steroids, the regular tapering schedule was applied. MMF 1-2 g/day was added to cyclosporine. If the patient was already receiving MMF (after RIC-HCT) or MMF failed to induce a CR, ECP was used. In cases of progressive skin GVHD and/or appearance of gastrointestinal and/or hepatic GVHD Xstage 2 under UVA-1 irradiation, phototherapy was immediately discontinued and systemic steroids, if not already started, were given.
UVA-1 phototherapy
For UVA-1 irradiation (340-400 nm), we used a system for whole-body treatment (Medisun 24000, Ho¨nle Medizintechnik GmbH, Kaufering, Germany . For patients responding to treatment, we scaled the frequency down to 3 times per week. After disappearance of cutaneous manifestations, we maintained therapy with 1-2 treatments per week for a further 1-2 weeks. Complete response was defined as a total clearing of skin lesions. Partial response was defined as clearing of more than 50% of the affected body surface. For assessment of response duration, patients were censored at the time of death or occurrence of chronic GVHD.
Results
In this cohort, UVA-1 irradiation as primary treatment for skin GVHD with the assigned 60 J/cm 2 or 40 J/cm 2 for patients with voriconazol was very well tolerated; side effects were reversible tanning and mild erythema in almost all patients. No serious side effects were noticed and no dose reductions or treatment interruptions were required because of side effects. Even patients receiving the potentially phototoxic antifungal voriconazole treatment did not show increased side effects.
Patients with acute GVHD of the skin received a median of 21 (range 2-55) sessions of UVA-1 irradiation as primary treatment with a median cumulative dose of 1075 (range 50-2645) J/cm 2, including a median of 3 (range 1-4) sessions as maintenance therapy over 1-2 weeks.
Responses to phototherapy occurred rapidly after a median of five sessions. Four patients with grade III GVHD showed progressive GVHD early despite concomitant steroids and UVA-1 therapy was discontinued after a median of two (range 2-5) sessions. Overall response of cutaneous GVHD to UVA-1 phototherapy occurred in 66 (94.3%) patients with a median response duration of 10 As expected, patients who received HCT after RIC (median age 61 years) were significantly older compared with patients who received HCT after more intensive conditioning (median age 44 years) (Po0.000). Nevertheless, the type of conditioning regimen had no impact on the stage and severity of acute GVHD of the skin, which tended to occur after a median of 36 days following HCT after RIC compared with an earlier onset at a median of 25 days after non-RIC HCT (P ¼ 0.08).
Although CR rates of acute GVHD of the skin following UVA-1 therapy for patients with RIC were lower compared with patients who received non-RIC HCT (27 (64.3%) vs 22 (81.5%) patients respectively), this was not statistically significant (P ¼ 0.12). Similarly, no statistically significant correlation between the severity of GVHD following RIC vs non-RIC and subsequent response to UVA-1 therapy was found (for RIC, CRs were achieved in 12/18 (66.7%) grade I, 10/18 (55.6%) grade II and 5/7 (71.4%) grade III acute GVHD cases. For non-RIC HCT, CRs were induced in 13/15 (86.7%) grade I, 8/8 (100%) grade II and 1/4 (25%) grade III acute GVHD cases).
GVHD after RIC required more treatment sessions with a median of 21 sessions per patient compared with a median of 16 sessions per patient after non-RIC HCT (P ¼ 0.04). Also, patients with acute GVHD of the skin following HCT after RIC required a higher median dose of UVA-1 irradiation (1095 J/cm 2 ) compared with a median dose of 640 J/cm 2 applied to patients after non-RIC HCT (P ¼ 0.001). Grade I GVHD after RIC required more intense UVA-1 therapy with a median of 1170 (range 250-2645) J/cm 2 vs a median of 610 (range 270-1835) J/cm 2 phototherapy for grade I after non-RIC HCT (P ¼ 0.001). On the other hand, treatment of grades II and III GVHD required similar UVA-1 intensities irrespective of the type of conditioning with a median of 1027 (range 250-2600) J/cm 2 applied in patients with RIC compared with a median of 955 (range 795-1490) J/cm 2 for patients with non-RIC HCT. In univariate analyses, underlying disease, age, stage, as well as severity of acute GVHD and gender did not have an influence on the efficacy of UVA-1 irradiation as primary treatment of acute skin GVHD, even though all nonresponders (n ¼ 4) in this study were male patients. Table 2 shows overall response, the incidence of CR and PR according to the stage and severity of GVHD, as well as type of conditioning.
Interestingly, the concomitant use of systemic steroids had no impact on the efficacy of UVA-1 therapy as primary treatment for acute GVHD of the skin.
After a median of 20 (range 5-41) sessions of phototherapy, systemic immunosuppression could be tapered in 24 (34.3%) patients (systemic steroids rapidly tapered and discontinued, n ¼ 14; MMF reduced, n ¼ 4; cyclosporine reduced, n ¼ 3 and two immunosuppressants tapered, n ¼ 3).
After a median follow-up of 18 (range 10-60) months, three (4.3%) male patients with a median age of 60 years developed neoplasia of the skin (one basal cell carcinoma 390 days after UVA-1, one squamous cell carcinoma and Bowen's disease 1590 days after UVA-1 and one superficial spreading melanoma 180 days after UVA-1). All patients received HCT after RIC (Table 3) . The dose and duration of UVA-1 irradiation in these patients were similar to other patients.
For the entire cohort, median survival time was 18 (2-60) months with 39 (55.7%) patients being alive. In total, 11 (15.7%) died due to relapse after a median of 5 (range 2-20) months. The incidence of non-relapse mortality was 28.6%. Infections occurring after a median of 5 (2-16) months were the main cause of death in 16 (22.9%) patients. Infections occurred equally in patients treated with UVA-1 only as primary treatment for GVHD and those who received systemic steroids simultaneously. Table 4 summarizes causes of death, severity and response of acute GVHD to UVA-1 phototherapy.
57 (81%) patients survived beyond day 100 after HCT and were evaluable for development of chronic GVHD, which was diagnosed in 28/57 (49%) patients. The median time interval from the end of UVA-1 therapy as primary treatment for acute GVHD and onset of chronic GVHD was 11 (range 1-28) months. Cutaneous involvement was present in 18 (64.3%) patients (limited skin, n ¼ 7; extensive skin, n ¼ 4 and both skin and other organ GVHD, n ¼ 7). The remaining 10 (35.7%) patients suffered from extracutaneous chronic GVHD without skin involvement (Table 4) . Type of conditioning regimen and type of UVA-1 in acute GVHD of the skin M Schlaak et al response to previous UVA-1 therapy did not influence the subsequent development of chronic GVHD of the skin. Similarly, the use of systemic steroids in the treatment of acute GVHD had no impact on the subsequent development of chronic GVHD (Table 4) .
Discussion
Involvement of the skin is the most frequent manifestation of acute GVHD. 1 Glucocorticoids remain the first-line therapy often in combination with other agents. 1, 2, [8] [9] [10] [11] The side effects of systemic steroids, such as increased risk of infections and increased relapse rate of the underlying disease, are well known. In addition, durable responses to first-line steroids are only seen in 20-40% of patients. 8, 11, 12 For these reasons, there is a real need for the development of non-pharmacological approaches for the treatment of acute GVHD of the skin.
Long-wavelength UVA (340-400 nm; UVA-1) therapy has been used in our department since 2002. On the basis of the promising data by Wetzig et al., 25 we treated 70 patients with acute cutaneous GVHD with UVA-1 as primary therapy. The median cumulative UVA-1 dose of 1075 J/cm 2 used in our cohort was comparable to that reported in the dose finding studies in atopic dermatitis. 27 UVA-1 treatment was very well tolerated with reversible tanning and mild erythema including patients requiring the antifungal voriconazole with its known phototoxic potential allowing a continuation of an effective oral antifungal treatment in an outpatient setting.
Our data show that UVA-1 therapy as primary treatment is highly effective in treating acute cutaneous GVHD with an overall response rate of 94.3% including 70% CRs.
At this point, it is difficult to compare the efficacy of phototherapy as the primary treatment for acute GVHD with that of systemic steroids, the gold standard in treating acute GVHD, as UVA-1 therapy was given for treatment of cutaneous manifestations only in a non-randomized fashion in our analysis.
Nevertheless, 47 (67.1%) patients including seven with cutaneous GVHD stage 3 did not receive steroids, but were offered UVA-1 therapy as primary treatment. With all the limitations of a retrospective analysis, our data suggest that the early initiation of UVA-1 therapy might allow the avoidance of systemic steroids and/or a more rapid Table 3 Characteristics of patients developing secondary skin neoplasia after UVA-1 treatment for acute GVHD (N ¼ 3) Table 4 Overview of mortality and chronic GVHD in patients treated with phototherapy for acute cutaneous GVHD (N ¼ 70)
Grade of acute GVHD (N)
Systemis steroids to treat acute GVHD (N)
Response of acute skin GVHD to UVA-1 (N) It is important to stress the fact that UVA-1 phototherapy was shown to be effective in treating acute skin GVHD only as all patients with visceral GVHD Xstage 2 were treated simultaneously with UVA-1 and systemic steroids.
Over the last few years, HCT following RIC has been increasingly used in patients with contraindications to receiving conventional HCT, such as age and/or comorbidities. The frequencies of RIC HCT have risen from less than 1% of all allogeneic HCT in 1998 to 34% in 2006. 28 Our study included 43 (61.4%) patients who received RIC HCT. As expected, these patients were significantly older compared with patients who received HCT following more intensive conditioning regimens (Po0.000).
To date, the impact of RIC on the incidence, severity or response of acute GVHD to treatment has not been evaluated in depth. In our analysis, patients with RIC demonstrated a later median onset of acute GVHD compared with non-RIC patients. This observation is in accordance with that reported by Perez-Simon et al. 29 Although it has been reported that RIC decreases the incidence and severity of acute GVHD when compared with non-RIC, [29] [30] [31] we could not demonstrate an influence of the type of conditioning regimen on the severity of acute cutaneous GVHD. However, patients with RIC required more treatment sessions and a higher median dose of UVA-1 irradiation for treatment of acute GVHD of the skin (mainly grade 1) compared with patients with non-RIC HCT. This might be due to an alteration in the pathophysiology of GVHD following RIC in contrast to non-RIC as published by Turner et al. 32 They demonstrated in a murine model that RIC-associated GVHD is characterized by lower production of tumour necrosis factor-a, increased T-regulatory cell numbers and a delayed emergence of activated donor DC in contrast to non-RIC. Their study suggests that DC contribute differently to GVHD in the RIC setting and that RIC alters the peritransplant milieu in the recipient favouring maintenance of functional host DC.
Nevertheless, UVA-1 irradiation seems to be a suitable and effective primary treatment option in all patients with acute GVHD of the skin irrespective of the type of conditioning regimen.
An important question is whether UVA-1 treatment of acute GVHD of the skin without systemic steroids could be another risk factor for later chronic GVHD besides the well identified risk factors, including prior acute GVHD, older patient age, use of female donors for male recipients, use of unrelated or HLA-mismatched donors and use of PBSCs as a source of stem cells. In our cohort, the subsequent development of chronic GVHD occurred irrespective of the type of conditioning regimen, type of response of acute GVHD to UVA-1 therapy and whether systemic steroids were used simultaneously with phototherapy to treat acute GVHD. Nevertheless, a larger number of patients and longer follow-up are needed to answer this question.
A second important concern is the known carcinogenic effect of UVA-1 (315-400 nm) therapy as a potential longterm adverse effect, though UVB radiation (wavelength band 280-315 nm) is considered to represent the most carcinogenic waveband. 33 Nucleic acids and proteins both absorb light within UVB range, peaking at 260 and 280 nm. Like UVB, UVA is able to mutate DNA. However, unlike UVB, UVA-mediated damage occurs indirectly through UV radiation absorption by oxygen species, or as shown in newer publications, by cyclobutane pyrimidine dimers. 34, 35 Development of malignant melanoma is considered to be unrelated to UVA irradiation and melanoma risk is not associated with cumulative, but rather with more intensive and intermittent exposure to sunlight. 36 Long-term observation is available for 8-methyoxypsoralen plus UV light treatment of 4799 immune-competent Swedish patients. 37 In this cohort, an increased risk for malignant melanoma was not found. On the other hand, there was an increased risk for squamous cell carcinoma with a relative risk of 5.6 (95% confidence interval 4.4-7.1) for men and 3.6 (95% confidence interval 2.1-5.8) for women.
In our cohort, we observed one case of basal cell carcinoma , one squamous cell carcinoma and one superficial spreading melanoma, which amounts to 4.3% of the entire population after a median follow-up of 18 (range 10-60) months.
Data on the development of non-melanoma skin cancer in immunosuppressed patients are mainly available for solid-organ transplant recipients who have a 65-to 250-fold increased risk of developing non-melanoma skin cancer compared with the general population, with the risk being highest for patients aged 50-60 years at the time of transplantation. 38 The Cancer Register of Saarland publishes an incidence of 70 non-melanoma skin cancer per 100 000 inhabitants in the general population per year, 39 so a cautious estimate of approximately a 40-fold higher risk of developing nonmelanoma skin cancer in our patients compared with the general population could be made.
Besides the carcinogenic effect of UVA-1 therapy and immunosuppression, long-term survivors after HCT have a generally increased risk of solid tumours over time with no evidence of a plateau. 40 In a collaborative study, 19 220 patients transplanted between 1964 and 1992 were analysed. There were 80 solid tumours, giving an observed/ expected ratio of 2.7. In patients surviving at least 10 years after HCT, the risk was increased 8-fold. The risk was increased significantly for melanoma, cancer of the buccal cavity, liver, central nervous system, thyroid, bone and connective tissue. Most striking was the link of squamous cell carcinoma with chronic GVHD and/or its treatment and male gender. Thus, a longer and close follow-up is mandatory for all patients after HCT.
In conclusion, UVA-1 treatment as primary therapy for acute GVHD of the skin is feasible, well tolerated and effective in an outpatient setting irrespective of age or type of conditioning. Systemic steroids might thus be avoided and/or tapered more rapidly in a proportion of patients. Nevertheless, patients must be followed carefully for early detection of possible secondary cutaneous malignancies. The encouraging results of this retrospective analysis, warrant future prospective clinical trials comparing UVA-1 therapy with standard treatment modalities for acute GVHD of the skin.
